# US 2021/0069307 A1 · Lyophilized factor ix formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069307 A1
- Document ID: US20210069307A1
- Status: Published application
- Kind: A1
- Application number: 16/995,173
- Filed: 2020-08-17
- Published: 2021-03-11
- Earliest claimed: 2014-03-24
- Assignees: Bioverativ Therapeutics Inc.
- Applicants: Bioverativ Therapeutics Inc.
- Inventors: Brian M. THOME; Cherie PARKHURST-LANG; Brandon W. LEVEILLE
- Web page: https://patentgrep.com/patent/US20210069307A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- F26B 5/06: the process involving freezing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- F26B: DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM (drying devices for combines A01D41/133; racks for drying fruit or vegetables A01F25/12; drying foodstuffs A23; drying hair A45D20/00; body-drying implements A47K10/00; drying household articles A47L; drying gases or vapours B01D; chemical or physical processes for dewatering or like separating liquids from solids B01D43/00; centrifugal apparatus B04; drying ceramics C04B33/30; drying yarns or fabrics in association with some other form of treatment D06C; drying frames for laundry without heating or positive air circulation, domestic laundry-or spin-driers, wringing or hot pressing laundry D06F; furnaces, kilns, ovens F27)

## Abstract

The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide.

## Claims

### Claim 1

A pre-lyophilization formulation comprising:
(a) a chimeric Factor IX (FIX) polypeptide, comprising FIX and a heterologous moiety that extends the half-life of the FIX;
(b) L-histidine;
(c) sucrose;
(d) mannitol; and
(e) polysorbate 20,
wherein the formulation has a fill volume of less than about 5 mL, less than about 4 mL, or less than about 3 mL and wherein each of (a)-(e) are at an amount per vial (mg/vial) sufficient to allow
(1) improved stability of the chimeric FIX polypeptide when lyophilized;
(2) reduced reconstitution time when lyophilized;
(3) reduced splashing onto a stopper comprising the formulation;
(4) reduced lyophilization cycle time;
(5) increased shelf-life of a lyophilate prepared from the pre-lyophilization formulation at room temperature; or
(6) any combinations thereof,
compared to a reference pre-lyophilization formulation,
wherein the reference formulation comprises (a)-(e) at the amount per vial identical to the pre-lyophilization formulation, but has a 5 mL fill volume.

### Claim 2 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the fill volume is about 4 mL, about 3.5 mL, about 3.0 mL, about 2.9 mL, about 2.8 mL, about 2.7 mL, about 2.65 mL, about 2.6 mL, about 2.5 mL, about 2.4 mL, about 2.3 mL, about 2.2 mL, about 2.1 mL, or about 2.0 mL.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the reduced reconstitution time is less than 1.5 minute, less than 1 minute, less than 50 seconds, less than 40 seconds, less than 30 seconds, less than 20 seconds, or less than 10 seconds.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the reduced lyophilization cycle time is about 4 days or less, about 3 days or less, about 2 days or less, or about a day or less.

### Claim at position 7

7-11. (canceled)

### Claim 12 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the formulation comprises about 200 IU/vial to about 10,000 IU/vial of the chimeric FIX polypeptide.

### Claim 13 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the chimeric FIX polypeptide comprises about 220 IU/vial, about 250 IU/vial, about 300 IU/vial, about 400 IU/vial, about 500 IU/vial, about 600 IU/vial, about 700 IU/vial, about 800 IU/vial, about 900 IU/vial, about 1,000 IU/vial, about 1,100 IU/vial, about 1,200 IU/vial, about 1,300 IU/vial, about 1,400 IU/vial, about 1,500 IU/vial, about 2,000 IU/vial, about 2,500 IU/vial, about 3,000 IU/vial, about 4,000 IU/vial, about 5,000 IU/vial, about 5,500 IU/vial, about 6,000 IU/vial, about 6,500 IU/vial, about 7,000 IU/vial, about 7,500 IU/vial, about 8,000 IU/vial, about 8,500 IU/vial, about 9,000 IU/vial, about 9,500 IU/vial or about 10,000 IU/vial.

### Claim 14 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the L-histidine is at a concentration between about 3 mg/mL and about 15 mg/mL.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the L-histidine is at a concentration of about 7.76 mg/mL.

### Claim 17 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the sucrose is at a concentration between about 10 mg/mL and about 50 mg/mL.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the sucrose is at a concentration of about 23.8 mg/mL.

### Claim 20 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the mannitol is at a concentration between about 20 mg/mL and about 100 mg/mL.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the mannitol is at a concentration of about 47.6 mg/mL.

### Claim 23 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the polysorbate 20 is at a concentration between about 0.01 mg/mL and about 5 mg/mL.

### Claim 24 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the polysorbate 20 is at a concentration of about 0.2 mg/mL.

### Claim 25 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the chimeric FIX polypeptide is at a concentration between about 80 IU/mL and about 2,750 IU/mL.

### Claim 26

A pre-lyophilization formulation comprising:
a. about 80 to about 2,750 IU/mL of a chimeric Factor IX (FIX) polypeptide, comprising FIX and Fc;
b. about 7.76 mg/mL of L-histidine;
c. about 47.6 mg/mL of mannitol;
d. about 23.8 mg/mL of sucrose; and,
e. about 0.2 mg/mL of polysorbate 20.

### Claim 27 (depends on 26)

The pre-lyophilization formulation of claim 26, wherein the formulation has a fill volume per vial of about 3 mL, about 2.9 mL, about 2.8 mL, about 2.7 mL, about 2.65 mL, about 2.6 mL, about 2.5 mL, about 2.4 mL, about 2.3 mL, about 2.2 mL, about 2.1 mL, or about 2.0 mL.

### Claim 28 (depends on 27)

The pre-lyophilization formulation of claim 27, wherein the formulation has a fill volume per vial of about 2.65 mL.

### Claim at position 25

29-57. (canceled)

### Claim 58 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the moiety extending half-life of FIX comprises an FcRn binding partner or an Fc region.

### Claim 59 (depends on 1)

The pre-lyophilization formulation of claim 1, wherein the chimeric FIX polypeptide comprises the FIXFc-sc polypeptide of SEQ ID NO: 2 and the Fc sc polypeptide of SEQ ID NO:4.

### Claim at position 28

60-104. (canceled)
